Baird Maintains Neutral on Elevance Health, Raises Price Target to $406
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $393 to $406.
Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $393 to $406.